XERIS PHARMACEUTICALS INC Research and Development Expense
XERIS PHARMACEUTICALS INC reported Research and Development Expense of $5.38 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-08-05
- XERIS PHARMACEUTICALS INC research and development expense for the quarter ending 2021-06-30 was $5.38M, a 1.78% increase year-over-year.
- XERIS PHARMACEUTICALS INC research and development expense for the quarter ending 2021-03-31 was $4.03M, a 39.33% decline year-over-year.
- XERIS PHARMACEUTICALS INC research and development expense for the quarter ending 2020-12-31 was $5.11M, a 58.86% decline year-over-year.
- XERIS PHARMACEUTICALS INC research and development expense for the quarter ending 2020-09-30 was $3.88M, a 75.02% decline year-over-year.
- XERIS PHARMACEUTICALS INC research and development expense for fiscal 2020 was $20.92M, a 65.38% decline from fiscal 2019.
- XERIS PHARMACEUTICALS INC research and development expense for fiscal 2019 was $60.44M, a 48.66% increase from fiscal 2018.
- XERIS PHARMACEUTICALS INC research and development expense for fiscal 2018 was $40.65M, a 101.60% increase from fiscal 2017.
- XERIS PHARMACEUTICALS INC research and development expense for fiscal 2017 was $20.17M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2021-06-30 | $5.38M 10-Q · filed 2021-08-05 | $9.41M 10-Q · filed 2021-08-05 | $14.53M derived: sum of 3 quarters · filed 2021-08-05 | $18.40M derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | $4.03M 10-Q · filed 2021-05-13 | $9.14M derived: sum of 2 quarters · filed 2021-05-13 | $13.02M derived: sum of 3 quarters · filed 2021-05-13 | $18.31M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-12-31 | $5.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $8.99M derived: sum of 2 quarters · filed 2021-03-09 | $14.28M derived: sum of 3 quarters · filed 2021-08-05 | $20.92M 10-K · filed 2021-03-09 |
| 2020-09-30 | $3.88M 10-Q · filed 2020-11-09 | $9.16M derived: sum of 2 quarters · filed 2021-08-05 | $15.81M 10-Q · filed 2020-11-09 | $28.23M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-06-30 | $5.29M 10-Q · filed 2021-08-05 | $11.94M 10-Q · filed 2021-08-05 | $24.36M derived: sum of 3 quarters · filed 2021-08-05 | $39.87M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $6.65M 10-Q · filed 2021-05-13 | $19.07M derived: sum of 2 quarters · filed 2021-05-13 | $34.58M derived: sum of 3 quarters · filed 2021-05-13 | $53.92M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $12.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $27.94M derived: sum of 2 quarters · filed 2021-03-09 | $47.27M derived: sum of 3 quarters · filed 2021-03-09 | $60.44M 10-K · filed 2021-03-09 |
| 2019-09-30 | $15.52M 10-Q · filed 2020-11-09 | $34.85M derived: sum of 2 quarters · filed 2020-11-09 | $48.02M 10-Q · filed 2020-11-09 | $60.41M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $19.33M 10-Q · filed 2020-08-10 | $32.50M 10-Q · filed 2020-08-10 | $44.89M derived: sum of 3 quarters · filed 2020-08-10 | $55.77M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $13.17M 10-Q · filed 2020-05-07 | $25.56M derived: sum of 2 quarters · filed 2020-05-07 | $36.43M derived: sum of 3 quarters · filed 2020-05-07 | $45.11M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $12.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $23.27M derived: sum of 2 quarters · filed 2020-03-12 | $31.94M derived: sum of 3 quarters · filed 2020-03-12 | $40.65M 10-K · filed 2020-03-12 |
| 2018-09-30 | $10.88M 10-Q · filed 2019-11-07 | $19.55M derived: sum of 2 quarters · filed 2019-11-07 | $28.26M 10-Q · filed 2019-11-07 | $34.84M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $8.68M 10-Q · filed 2019-08-06 | $17.39M 10-Q · filed 2019-08-06 | $23.97M derived: sum of 3 quarters · filed 2019-08-06 | $29.69M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $8.71M 10-Q · filed 2019-05-09 | $15.29M derived: sum of 2 quarters · filed 2019-05-09 | $21.02M derived: sum of 3 quarters · filed 2019-05-09 | $25.22M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $6.58M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $12.30M derived: sum of 2 quarters · filed 2019-03-06 | $16.50M derived: sum of 3 quarters · filed 2019-03-06 | $20.17M 10-K · filed 2019-03-06 |
| 2017-09-30 | $5.72M 10-Q · filed 2018-11-08 | $9.93M derived: sum of 2 quarters · filed 2018-11-08 | $13.59M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $4.20M 10-Q · filed 2018-08-14 | $7.86M 10-Q · filed 2018-08-14 |